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Abstract
Inflammatory bowel diseases are systemic disorders that can manifest in any location. The problem of respiratory system 
involvement is very important form clinical point of view. In the article we try to systematize the current knowledge on this topic.
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Introduction
Inflammatory bowel disease (IBD) is a group 
of chronic inflammatory disorders of small and 
large intestine, characterised by relapsing pattern. 
IBD comprises ulcerative colitis (UC), Crohn’s 
disease (CD) and a subgroup of colitis difficult 
to classify as either form. The IBD incidence rate 
in Europe is 35 per 100 000 person-years and is 
constantly growing. It is estimated that 0.3% of 
the European population is affected by IBD. In 
most regions UC is more frequent than CD [1]. 
The pathogenesis of IBD is not fully understood. 
Genetic predisposition, environmental factors 
and abnormal immune processes are believed to 
be involved [2]. In 15–20% of UC patients and 
20-40% of CD patients, so-called extraintestinal 
manifestations (EIM) of IBD are present [3–7]. 
Most commonly, involvement of central and pe-
ripheral joints, skin, eyes and the hepatobiliary 
system is seen [3–7]. It is most probably related 
to the presence of circulating antibodies against 
a colonic epithelial antigen that is shared among 
these organs [8]. The evidence of other organs 
involvement is smaller; however, it seems that 
practically any organ can be affected. Involve-
ment of the respiratory tract is rare, but remains 
an object of constant interest. 
Mechanisms of interaction between the 
gastrointestinal and respiratory tracts in IBD
Respiratory tract diseases in patients suffe-
ring from IBD may result from the following:
1) incidental coexistence, 
2) extraintestinal manifestation of IBD,
3)  local complications of IBD: colobronchial or 
oesophagopulmonary fistulae,
4)  side-effects of IBD treatment: infections, 
drug-induced pneumotoxicity 
5)  hypercoagulability: pulmonary embolism.
The hypothesis that IBD is associated with 
respiratory morbidity is based on both theoretical 
and practical grounds. The gastrointestinal tract 
and respiratory tract have common embryonic ori-
gin from the primitive foregut and share structural 
similarities [9]. The presence of the mucosa-as-
sociated lymphoid tissue in both systems seems 
to play a key role. It is believed that following 
mechanisms are involved in the development 
of inflammation within the respiratory system 
in the course of IBD: a) migration of activated 
lymphocytes from the gastrointestinal tract to the 
airways, which could shift inflammatory process 
from one site to the other, b) presence of unusual 
antigens such as bacteria, digestive enzymes, and 
dietary particles, appearing in circulation due to 
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loss of epithelial barrier function of the bowels, 
c) presence of antibodies and immune complexes 
that can cross-react in various areas of the human 
body [2, 10].
Epidemiology
There is no proper epidemiological investi-
gation proving respiratory diseases to be EIM of 
IBD. Large original studies on EIM in IBD either 
do not mention such relationship or report it as 
a very small percentage of patients [4–6, 11, 12]. 
On the other hand, there is a large number of case 
reports that suggest existence of the phenomenon. 
First such reports appeared in the second half of 
the 20th century [13, 14] and hundreds have been 
published since then [15–18]. It is believed that 
gut-lung communication is bidirectional, so two 
ways of approach to the subject can be found 
in the literature. One focuses on the respiratory 
tract diseases occurrence in IBD patients, and 
the other one on IBD occurrence in patients with 
respiratory diseases. 
Retrospective analysis conducted by Raj 
et al. [19] seems to be one of the most noteworthy 
in terms of epidemiology. Among 2192 patients 
with airways disease seen in one chest clinic, they 
found 37 (1.7%) patients with histologically con-
firmed diagnosis of IBD. Nine (24%) of them had 
asthma, another 9 (24%) COPD, 8 (22%) chronic 
non-productive cough alone, 7 (19%) bronchiec-
tasis, 4 (10%) chronic bronchitis. When compared 
to data on local IBD prevalence, it appeared that 
there were significantly more cases of IBD among 
patients with airways diseases than it would be 
expected in a similar-sized general population 
— odds ratio (OR) was 4.26 for all IBD, 5.96 for 
CD, 4.21 for UC. The association was particular-
ly strong with airways diseases associated with 
productive cough. IBD was more frequent in all 
patterns of airways diseases except asthma. There 
are, however, studies showing contrary results on 
asthma-IBD association. On the basis of admini-
strative data from health databases, they show 
higher prevalence of asthma in both UC and CD 
patients [7], or higher prevalence of UC and CD 
in asthma patients group [7, 20, 21], compared 
to control groups. Bernstein et al. [7] found that 
the risk of asthma was 50–70% higher in their 
patients with UC and 30–40% higher in their 
patients with CD, compared to population-based 
controls. Data from the same studied population, 
but looked at in a different way, indicated that IBD 
risk in asthma patients is also higher than in the 
control group: prevalence ratio for UC was 1.56 
and for CD 1.38. Brassard et al. [20] reported on 
the incidence of CD in asthma patients 27% higher 
than in the general population, the incidence of 
UC did not differ significantly from the one in the 
general population. The incidence of CD was also 
significantly, i.e. 55% higher in COPD patients 
in comparison to the control group. Association 
between asthma and IBD was also suggested by 
Hemminki et al. [21]. Another study that showed 
a significantly increased prevalence of respira-
tory symptoms in subjects with IBD was one by 
Birring et al. [22]. They compared the frequency 
of respiratory symptoms in 64 IBD patients and 
124 healthy persons. The OR for breathlessness, 
sputum production and cough was 3.4, 2.5 and 
1.8, respectively. Wheeze and nocturnal cough 
were equally prevalent in both groups. Patients 
with CD were 1.4–3.0 times more likely to report 
respiratory symptoms than patients with UC. 
Other studies showed that respiratory symptoms 
were reported by 26–48% of IBD patients, which 
was more frequent than in healthy people [23–27].
Various abnormalities in pulmonary func-
tion tests (PFT) in IBD patients have also been 
reported. Up to 58% of these patients had at least 
one abnormal value in PFT [23–28]. Impairment 
of diffusion lung capacity for carbon monoxide 
(DLCO) was most commonly found [23–28]. In 
one of the studies, a group of IBD patients had 
significantly lower mean DLCO and higher ratio of 
residual volume (RV) to total lung capacity (TLC) 
than a control group [23]. In another study, mean 
values of forced expiratory volume in one second 
(FEV1), ratio of FEV1 to forced vital capacity (FVC), 
maximum mid-expiratory flow (MMEF), DLCO, 
and carbon monoxide transfer coefficient (Kco) were 
lower in IBD patients than in healthy subjects [26]. 
Abnormalities in PFT could be found even in non-
smoking IBD patients with no history of respiratory 
tract disorder and with normal chest x-ray [28]. 
Bronchial hypersensitivity in provocation tests 
with methacholine was observed in 17–71% of IBD 
patients, more often than in control groups [29–31].
Abnormalities in high resolution computed 
tomography (HRCT) of the lungs were noticed in 
up to 64% of IBD patients, even in the absence 
of clinical symptoms of respiratory disease. Most 
prevalent findings included as follows: peribron-
chial thickness, bronchiectasis, air trapping, 
reticular pattern, ground glass opacifications, 
emphysema, nodular opacifications, mediastinal 
lymphadenopathy, parenchymal opacifications, 
and rarely pleural abnormalities [24, 26, 27, 32].
Sputum and bronchoalveolar lavage (BAL) 
fluid in IBD patients have also been investigated. 
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Mohamed-Hussein et al. [25] found that induced 
sputum of UC patients contained significantly 
more lymphocytes and eosinophils compared 
to healthy volunteers. Other authors reported 
on higher percentage of sputum eosinophils but 
not lymphocytes in UC patients [33] and CD pa-
tients [34]. Fireman et al. [35], on the other hand, 
found significantly higher lymphocyte count in 
induced sputum of non-smoking and respiratory 
symptoms free CD patients than in controls; in 
65% of their patients, the CD4/CD8 lymphocytes 
ratio was higher than 2.5. Bonniere et al. [36] 
compared BAL fluid of 22 patients with CD, 
free of clinical pulmonary symptoms and with 
normal chest roentgenograms, with 25 control 
subjects. Total number of cells in BAL fluid was 
identical, but percentages of lymphocytes were 
higher in patients than in controls. In 54% of the 
patients, bronchoalveolar lymphocyte count was 
above 18%. There was no correlation between 
abnormal BAL findings and activity of the inte-
stinal disease, presence of the disease at other 
locations, or PFT results. Karadag et al. [32] exa-
mined BAL fluid of 10 UC patients, all were free 
of respiratory symptoms and had normal chest 
x-ray. Alterations of different types were found in 
50% of them. In all patients with abnormal BAL, 
lymphocytes constituted more than 15% of cells. 
Transbronchial lung biopsy was available in all 
10 patients, and it revealed the following: normal 
histology in 2 cases, lymphocytes accumulation 
in the interalveolar spaces and interstitial fibrosis 
in the remaining cases. 
Another tool that has been used in research 
on latent respiratory tract involvement in the 
course of IBD was measurement of exhaled ni-
tric oxide (eNO). This parameter is considered 
to be a marker of airway inflammation. At least 
three independent authors found increased eNO 
in IBD patients compared to control subjects 
[37–39].
There were few attempts to assess alveolar 
epithelial permeability in respiratory symptoms 
free, non-smoking IBD patients with the use 
of technetium-99m diethylene triamine penta 
acetic acid (Tc-99m DTPA) aerosol scintigraphy. 
The increased rate of DTPA clearance indicates 
inflammation or lung insults of any cause. In 
two of three published papers, a significantly 
higher alveolar epithelial permeability was 
reported in IBD patients compared to healthy 
people [40, 41]. In the third study, no evidence 
of abnormal lung permeability in patients with 
IBD was found [42]. 
Respiratory tract involvement according  
to anatomic site
Airways diseases — larynx, trachea, 
bronchi, bronchioli
According to published data, EIM of IBD 
can occur anywhere along the airways; however, 
large and medium-sized bronchi were the most 
common location — 39–50% of published cases 
[16, 18, 43]. In 66% of IBD patients with coexi-
sting bronchi disease, bronchiectasis was diagno-
sed [16]. Bronchiectasis associated with IBD may 
be more extensive and severe, compared to bron-
chiectasis related to other aetiology. The second 
common pathology was chronic bronchitis [15, 
16, 18]. Productive cough with abundant amounts 
of purulent sputum dominated in both bronchiec-
tasis and chronic bronchitis [14, 43–45]. Despite 
purulent character of the sputum, cultures were 
usually negative [14]. Increased percentage of 
neutrophils was seen in BAL fluid, and micro-
scopic study of bronchial mucosal biopsy showed 
infiltrates rich in lymphocytes and plasmatic 
cells [43]. Bronchiectasis and chronic bronchitis 
seemed to occur more frequently in the course of 
UC than CD [16, 18, 43]. Some authors argued that 
chronic bronchitis associated with IBD responded 
well to inhaled glucocorticosteroids [43, 46]. 
A rare form of respiratory tract involve-
ment is airway stenosis. It may occur at any 
level from the larynx to the segmental bronchi 
[16, 43, 47–49]. Clinical presentation in these 
cases included dyspnoea, fever, expectoration, 
stridor and/or wheeze [16, 43, 47–49]. Endoscopic 
studies revealed polypoid or pseudotumoural 
structures and/or circumferential inflammation 
obstructing the airway lumen. These lesions 
were friable and haemorrhagic [16, 43, 47–49]. 
Histological examination showed granulation 
tissue and mixed inflammation with domination 
of lymphocytes and plasma cells [43, 47–49]. 
Airway obstruction was very severe in some cases. 
Treatment was targeted at IBD control, it is based 
on glucocorticosteroids and aminosalicylates. In 
some cases a mechanical dilatation or laser abla-
tion were necessary [16, 43, 47–49].
Diseases of the small airways were less frequ-
ent, they constituted 3–10% of all cases of respi-
ratory diseases in IBD patients [18]. However, 
subclinical involvement detected by HRCT and 
PFT is believed to be more common [24, 27, 30, 
32, 50]. Usual symptoms of bronchiolitis included 
dry or productive cough, progressive breathles-
sness, wheezes on auscultation. Changes on ima-
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ging studies of the lungs include the following: 
air-trapping, tree-in-bud opacifications, ground-
glass opacifications, mosaic pattern, centrilobular 
nodules [16, 18, 43]. Various histological patterns 
were present, namely non-specific fibrosing and 
stenosing chronic bronchiolitis, bronchiolitis 
obliterans, granulomatous bronchiolitis, diffuse 
panbronchiolitis [12, 18, 32, 43]. Response to glu-
cocorticosteroids treatment also varied [18, 43].
Parenchymal diseases
A broad spectrum of lung parenchymal dise-
ases was observed in IBD patients:, i.e. organizing 
pneumonia — the most common, eosinophilic 
pneumonia, interstitial pneumonia with non-
caseating granulomas, nonspecific interstitial 
pneumonia, desquamative interstitial pneumonia, 
pulmonary fibrosis, nodules [12, 15–18, 43, 51]. 
The main symptoms included exertional dysp-
noea, dry or productive cough, fever, pleuritic 
chest pain. Bilateral crackling, rales and less 
frequently wheezing could be heard on chest 
auscultation. Respiratory failure was not rare, 
sometimes intubation and mechanical ventilation 
was needed. Radiologic studies revealed bilateral 
abnormalities of various types. The most com-
mon abnormalities in pulmonary function tests 
were decreased TLC and DLCO. The treatment 
consisted of systemic glucocorticosteroids. The 
prognosis was usually good, however, fatal out-
comes have also been reported [12, 15–18, 43].
The coexistence of IBD and pulmonary sar-
coidosis is a subject of special interest. Black 
et al. [16] found 53 such cases in the literature 
published up to the year 2007, so sarcoidosis wo-
uld have been the most frequent form of the lung 
involvement if it had been considered an EIM of 
IBD. Sarcoidosis was diagnosed in both UC and 
CD patients. More attention is paid to sarcoidosis 
in CD because there are some similarities between 
them: the presence of noncaseating epithelioid 
granulomas, dominance of type 1 helper lym-
phocytes in the inflammatory process, interac-
tion between genetic and environmental factors 
in the diseases pathomechanisms. Differential 
diagnosis between CD and gastro-intestinal sar-
coidosis is very difficult. In UC, inflammatory 
process has a different characteristic, with type 2 
helper lymphocytes playing a main role and 
mixed inflammatory infiltrations accumulating in 
crypt abscesses. Nevertheless, in 2009, the British 
researchers demonstrated that UC, but not CD, 
was more prevalent in the population of sarcoido-
sis patients compared to the general population 
[52]. Interestingly, serum angiotensin converting 
enzyme (sACE) activity in IBD patients was lower 
or the same as in the control group [36, 53, 54]. 
In the study confined to active IBD, sACE activity 
was significantly higher in UC patients compared 
to CD patients and healthy subjects, but was still 
significantly lower than in patients with acute 
sarcoidosis [55]. 
One of possible radiological presentations of 
pulmonary involvement in the course of IBD are 
lung nodules, sometimes with cavitations within 
them [43, 56–61]. Histopathological verification 
of such findings has revealed the following: ne-
crobiotic nodules composed of sterile aggregates 
of neutrophils containing areas of necrosis — 
most frequently, bronchiolitis obliterans with 
organizing pneumonia, noncaseating epithelioid 
granulomas, heterogeneous lymphoid infiltra-
tions, interstitial fibrosis and deposits of amylo-
id A component. Most of the reported patients 
were treated with systemic glucocorticosteroids 
and/or infliximab, and regression of pulmonary 
nodules was observed during the follow-up. The 
spontaneous resolution of the pulmonary nodules 
was also seen in few patients. Resolution, either 
spontaneous or during treatment, was very slow 
in some cases [43, 56–61].
Pleura
Pleuritis is rare in the course of IBD. Usually, 
it accompanies parenchymal diseases or colo-
bronchial fistulae. It may also be a part of serositis 
of unknown aetiology, in these cases pericarditis 
is present too [16, 43].
Drug-related pulmonary toxicity
The medications used for IBD treatment 
include as follows: a) anti-inflammatory drugs: 
aminosalicylates (sulphasalazine, mesalazine, 
olsalazine, balsalazide), glucocorticosteroids, b) 
immunosuppressants: azathioprine, 6-mercapto-
purine, methotrexate, c) anti-TNF drugs: inflixi-
mab, adalimumab. All these medications, with 
the exception of glucocorticosteroids, are well 
known for their possible lung toxicity [62–71]. 
The assumed lung-toxicity manifests itself mostly 
as interstitial lung diseases such as eosinophilic 
pneumonia, organizing pneumonia, interstitial 
lung fibrosis, interstitial pneumonia with non-
necrotizing granulomas, not specified interstitial 
pneumonia, bronchiolitis [60–69]. Rarely drug-
-induced toxicity manifests itself as pleuritis 
[72–74]. There are no differences between symp-
toms and radiological features of the respiratory 
tract diseases appearing as a consequence of 
drug toxicity and in other circumstances [62–71]. 
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There is no single test that could differentiate 
between drug — related and drug-unrelated 
pulmonary disorder, either. Factors in favour 
of a drug-induced pathology are the following: 
clear time relation between a medication com-
mencement and a disease onset, the presence 
of blood eosinophilia, disease resolution after 
medication withdrawal. The literature indicates 
that the majority of reported lung diseases in IBD 
patients is suspected to be drug-related [17, 43]. 
The management of such complications requires 
the withdrawal of suspected medication. Syste-
mic glucocorticosteroids are commonly used in 
addition [62, 67, 70]. It is always necessary to 
exclude infective aetiology in patients treated 
with immunosuppressants or biological drugs, 
tuberculosis and opportunistic pathogens should 
be also taken into consideration [75–80]. Lung 
complications of IBD treatment may be fatal 
[62, 67, 70, 77]. 
Colobronchial fistulae
Fistulae between the gastrointestinal tract 
and neighbouring structures can be seen in CD 
patients. There are several reports on oesophago-
bronchial [81–83], colobronchial (splenic flexure 
area) [84–88], and ileobronchial [89] fistulae. 
Clinical and radiological presentation was that of 
pneumonia, typically with pleural effusion and 
anaerobic flora on sputum culture. Surgical tre-
atment was usually necessary. Pulmonary fistulae 
should be always considered in patients with CD 
and difficult to treat pneumonia [81–88].
Thromboembolic disease
IBD is a well documented risk factor for 
thromboembolic disease (TED), with strength 
similar to that of a cancer [90]. IBD doubles the 
risk of TED [91]. The risk is dependent on the 
activity of IBD, in active disease it is 8 times hi-
gher than in the general population [92]. TED is 
more prevalent in CD patients when the disease 
involves the colon, and in UC patients when the 
disease is more extensive [93]. The risk of TED re-
currence after anticoagulant treatment completion 
is also increased [94]. The reason for higher TED 
risk in IBD remains obscure, it is believed to be 
complex. Beside the hypercoagulability related to 
inflammation, the role of various other acquired 
and congenital factors is postulated. There is no 
evidence for higher prevalence of thrombophilia 
in patients with IBD and TED, in comparison to 
IBD patients without TED [95]. The treatment of 
TED in IBD patients is the same as in the general 
population; however, it may be more challenging 
due to increased risk of gastrointestinal bleeding 
in IBD. The data on effectiveness and safety of 
chronic anticoagulation as a primary prophylaxis 
of TED in IBD is lacking. 
Time frame
In most cases, IBD preceded onset of respi-
ratory symptoms, in some patients they occurred 
concomitantly, and in others respiratory symp-
toms developed before IBD. The occurrence of 
IBD and respiratory disease may be separated by 
days or by decades [12, 14, 43, 45, 51]. Bronchial 
disorders usually developed after IBD diagnosis, 
while about 30% of bronchiolitis cases were re-
cognised before IBD [16, 17]. Of special interest 
is development of bronchiectasis and chronic 
bronchitis after a colectomy; in 50–60% of repor-
ted cases, it happened within a first year after the 
surgery [16, 18, 43]. Moreover, colectomy did not 
improve already existing respiratory symptoms 
[14, 51]. There were also rare cases of interstitial 
lung disease appearing after colectomy for UC 
[96, 97].
 Serositis, not related to drug toxicity, deve-
loped in most cases during IBD exacerbation or 
the first episode of the disease [43].
Respiratory disease depending on IBD activity
Few studies dealt with relationship between 
respiratory symptoms and activity of IBD. In the 
study by Birring et al. [22], there was a trend for 
those with active inflammatory bowel disease to 
report more symptoms, compared to those whose 
IBD was in remission. Yilmaz et al. [26] found 
association of increased respiratory symptom 
score with high endoscopic activity index in UC 
patients, but there was no correlation between 
respiratory symptoms and clinical activity of 
bowel disease. Alterations in PFT were more 
frequent in patients with active IBD as well 
[24, 28, 98]. Decrease in FEV1, FVC, FEV1/VC, 
MMEF, and DLCO was most commonly repor-
ted [25, 26, 28, 98], some authors also noticed 
increase in RV, RV/TLC, and functional residual 
capacity [23, 28, 99] in active period of IBD, 
compared to a period of remission of the disease. 
No relationship was found between duration of 
IBD and pulmonary function test results [26]. 
Bronchial hyperresponsiveness on methacholine 
challenge was independent of activity, extent and 
time of duration of IBD [29–31]. Exhaled NO cor-
related positively with IBD activity [37–39], but 
no relation was found for alveolar epithelial per-
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meability measured with the use of Tc-99m DTPA 
aerosol scintigraphy [40, 41]. Data on relationship 
between IBD activity and chest HRCT picture are 
discrepant. Some researchers reported on more 
prevalent lung HRCT abnormalities in patients 
with active IBD compared to patients with IBD in 
remission [24], others were unable to find such 
correlation [26]. No dependency between IBD 
duration and alterations on chest HRCT scans 
was identified [26]. Connection with IBD activity 
was found neither for lymphocyte nor eosinophil 
count in sputum [25]. Differential cell count in 
BAL fluid was not associated with IBD activity 
either [32–36]. 
The analysis of numerous case reports and 
case series showed that respiratory symptoms 
could develop in association with IBD flare as 
well as during remission of the disease, in some 
patients concomitant exacerbations of bowel and 
respiratory symptoms were reported [14, 100].
Summary
The literature suggesting the respiratory 
involvement in the course of IBD is very rich; ho-
wever, the proof that respiratory diseases are more 
prevalent in IBD patients than in the general po-
pulation is still lacking. The awareness of possible 
respiratory complications in IBD patients should 
be present in clinical practice, as some of them 
may be very severe, even life-threatening. The lung 
toxicity of medications used for IBD should also be 
kept in mind, as it is believed to be responsible for 
most of respiratory complications in IBD patients. 
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